Phase imaging company, Iatia Limited (ASX:IAT) is advancing its global business opportunities, receiving statements of intent to progress from manufacturers in the ophthalmology and semiconductor quality assurance markets (identities subject to confidentiality agreements).

CEO, Mr Laycock stated, "Following the successful visit to Melbourne in February by the ophthalmology manufacturer, we are collaborating on a prototype that will be built and delivered to us for testing with our Quantitative Phase Imaging (QPI) software.

"We expect this phase of work to be completed over the next few months. At completion a commercial collaborative agreement to bring to market an ophthalmic product based on our technology is expected.

"Additionally, as a result of our proof of concept work with the semiconductor manufacturer they have purchased a QPI software development licence to perform their detailed evaluation of the technology. Results of the evaluation are anticipated by the end of this financial year.

"Our ongoing work with the defence community coupled with these recent business developments continues to strengthen Iatia's market position," Mr Laycock said.

Iatia is committed to open and continual communication with its shareholders regarding the development of all business opportunities.